Each round of Medicare drug-price negotiations reshapes how manufacturers price, package, and defend their products. For the first time, the rules for the next round are being written directly into federal regulation. In a recent article by Bloomberg Law, the publication examined that shift. Constance A. Wilkinson, a Member of the Firm at Epstein Becker Green who focuses on drug pricing and reimbursement policy, was among the attorneys who weighed in on what it could mean for manufacturers.